FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The most substantive healthcare contribution of the week came from the latest issue of JAMA, where 2014 Lasker Award winner Mary-Claire King, writing with several colleagues from Israel, audaciously suggested that all adult women should be screened for defined categories of BRCA1 and BRCA2 mutations.
In a new study, 10.9 percent of antibiotic and tuberculosis drug samples that claimed to be made in India and were sold around the globe failed a basic assessment of quality.
The promise of wearables for medicine includes the opportunity for health measurement to participate more naturally in the flow of our lives, and provide a richer and more nuanced assessment of phenotype than that offered by the traditional labs and blood pressure assessments now found in our medical record.
Writing in the New York Times Magazine last Sunday, computer science graduate student Yiren Lu offered an unusually eloquent and nuanced account of today’s Silicon Valley start-up scene.
If greater ownership of health data leads us to feel a greater sense of ownership of our health, a sense that we have the ability not only to maintain our health information, but also to influence, through our behavior, the data that’s collected – what a powerful and beneficial transformation this could be.
The challenges of moving a health-related technology from promise to impact are illustrated nicely by two recent attempts to carefully evaluate the benefits of intriguing new devices.
A new regulation proposed by the Food and Drug Administration will compel generic drug makers to update their labels to reflect “new” safety issues. This new rule is a poor tool for keeping generic drug labels up-to-date, and it will come at a significant cost to consumers. If public health is the true imperative for this change, the FDA can address the generic labeling issues in far better ways.
As busy as the digital health space has been lately, one group of stakeholders has been conspicuously absent from the proceedings: pharma companies. Shame on anyone who is surprised.
We welcome you to join us as a panel of economists discuss US wage and price prospects in the coming months and the implications for the Federal Reserve’s current unorthodox monetary policy.